TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8707972

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg q.i.d. plus scaling
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg q.i.d. alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scaling plus placebo q.i.d.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo q.i.d. alone
Number of subjects: 30
Study: 1649971

Group type: EXPERIMENTAL
Intervention: Foscarnet (40 mg/kg IV every 8 hours)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vidarabine (15 mg/kg IV per day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vidarabine
Number of subjects: 14
Study: 6341914

Group type: EXPERIMENTAL
Intervention: 1% solution of fenoprofen sodium
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30963330

Group type: EXPERIMENTAL
Intervention: Myths vs. facts booklet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 60
Study: 30236110

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Inhaled saline (4 ml)
Number of subjects: 16
Study: 29231358

Group type: EXPERIMENTAL
Intervention: Regulating Conception‐Governor Vessel acupuncture method
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clomiphene (50 mg per day for 5 consecutive days)
Number of subjects: 100
Study: 24640990

Group type: EXPERIMENTAL
Intervention: 2 × 1000 mg rituximab
Number of subjects: 22

Group type: COMPARATOR
Intervention: 2 × 500 mg rituximab
Number of subjects: 22
Study: 22946762

Group type: EXPERIMENTAL
Intervention: Naloxone infusion (0.25 μg/kg/h for 24 h)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 90
Study: 19164398

Group type: EXPERIMENTAL
Intervention: Virtual environment training (5 one-hour sessions)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Attention control training (5 one-hour sessions)
Number of subjects: 13
Study: 17137561

Group type: EXPERIMENTAL
Intervention: Intranasal administration of 24 IU oxytocin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17069221

Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin injections
Number of subjects: 0
Study: 12517044

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (containing antigens B/Yamanashi/166/98, A/New Caledonia/20/99 (H1N1), and A/Panama/2007/99 (H3N2))
Number of subjects: 65

Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 65
Study: 9753207

Group type: EXPERIMENTAL
Intervention: Intravenous dolasetron mesylate (200 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral dolasetron mesylate (200 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Urinary excretion of hydrodolasetron and its metabolites
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dolasetron
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 36
Study: 7826913

Group type: EXPERIMENTAL
Intervention: Mx 2% topical solution
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 3042005

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (3 grams intravenously in a 60 ml solution, repeated 6 times with 12-hour intervals)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 31655378

Group type: EXPERIMENTAL
Intervention: SSRI+CBT (escitalopram 20 mg daily, 10 mg first week)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo+CBT
Number of subjects: 47
Study: 30955982

Group type: EXPERIMENTAL
Intervention: LBRV-PV (Liquid Bovine-Human Reassortant Pentavalent Vaccine)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Rotasiil® (Lyophilized Bovine-Human Rotavirus Reassortant Pentavalent Vaccine)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: LBRV-PV Lot A
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: LBRV-PV Lot B
Number of subjects: 1500
Study: 28919716

Group type: EXPERIMENTAL
Intervention: RDX7675 (reconstituted in water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RDX7675 (high-viscosity vanilla)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium polystyrene sulfonate (SPS)
Number of subjects: 0
Study: 24192128

Group type: EXPERIMENTAL
Intervention: Dietetic assessment, nutrition intervention and follow‐up in addition to regular community hospital interface programme support (Intervention group, n=9)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Regular treatment from community hospital interface programme nursing staff (Control group, n=10)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dietetic assessment, nutrition intervention and follow‐up (Intervention group)
Number of subjects: 24
Study: 23611572

Group type: EXPERIMENTAL
Intervention: Pediatric formulation of bosentan (64 mg as 2 pediatric tablets of 32 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Adult formulation of bosentan (62.5 mg as 1 adult tablet)
Number of subjects: 16
Study: 21561527

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1,000 mg) + Ibuprofen (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen (1,000 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen (325 mg) + Codeine (30 mg)
Number of subjects: 0
Study: 19136749

Group type: EXPERIMENTAL
Intervention: Amiodarone (3 mg/kg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 82
Study: 17370497

Group type: EXPERIMENTAL
Intervention: Surround needling plus surround moxibustion
Number of subjects: 72

Group type: COMPARATOR
Intervention: Surround needling (control)
Number of subjects: 72
Study: 15209182

Group type: EXPERIMENTAL
Intervention: MRI scan
Number of subjects: 118

Group type: COMPARATOR
Intervention: Arthroscopy
Number of subjects: 118
Study: 11355042

Group type: EXPERIMENTAL
Intervention: 1 mg oral micronized E2 daily for 16 months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Transdermal E2 delivered at a rate of 0.05 mg/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Transdermal E2 delivered at a rate of 0.1 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo patch for 9 months
Number of subjects: 33
Study: 9150323

Group type: EXPERIMENTAL
Intervention: Exacerbation of bronchitis (E)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Chronic bronchitis patients
Number of subjects: 13
Study: 8035241

Group type: EXPERIMENTAL
Intervention: Updated management approach for postdate pregnancy
Number of subjects: 0
Study: 3109581

Group type: EXPERIMENTAL
Intervention: Positive consultation (with treatment)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Positive consultation (without treatment)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Negative consultation (with treatment)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Negative consultation (without treatment)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Treated group (positive or negative consultation)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Untreated group (positive or negative consultation)
Number of subjects: 200
Study: 2550696

Group type: EXPERIMENTAL
Intervention: Lisinopril (5 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Indomethacin (150 mg/day)
Number of subjects: 12
Study: 31182142

Group type: EXPERIMENTAL
Intervention: Implementation of the aseptic practice bundle
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Aseptic practice observation
Number of subjects: 10000
Study: 28190152

Group type: EXPERIMENTAL
Intervention: Zirconia primary crowns
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cobalt‐chromium alloy primary crowns
Number of subjects: 56
Study: 25770419

Group type: EXPERIMENTAL
Intervention: Movement Control exercises (MC)
Number of subjects: 106

Group type: COMPARATOR
Intervention: General Exercise (GE)
Number of subjects: 106
Study: 23965158

Group type: EXPERIMENTAL
Intervention: Psoriasis skin lesions
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Psoriasis serum
Number of subjects: 89
Study: 21831438

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg/HCT 12.5 mg
Number of subjects: 253

Group type: COMPARATOR
Intervention: Candesartan 16 mg monotherapy
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg/HCT 12.5 mg
Number of subjects: 253

Group type: COMPARATOR
Intervention: Candesartan 32 mg monotherapy
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Candesartan-HCT combination therapy
Number of subjects: 253

Group type: COMPARATOR
Intervention: Candesartan monotherapy
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg
Number of subjects: 253
Study: 19217077

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day to 150 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 17146377

Group type: EXPERIMENTAL
Intervention: HMR 3339 50 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Raloxifene 60 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: HMR 3339 2.5 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: HMR 3339 10 mg
Number of subjects: 94
Study: 15070225

Group type: EXPERIMENTAL
Intervention: Direct training group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Indirect training group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 11314743

Group type: EXPERIMENTAL
Intervention: High-dose intravenous corticosteroid therapy (1 g of methylprednisolone diluted in 250-500 ml of physiological solution for 6 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Oral prednisone (60-80 mg/day progressively reduced every 2 weeks for a total duration of 4-6 months)
Number of subjects: 51
Study: 9467724

Group type: EXPERIMENTAL
Intervention: Aluminum exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 0
Study: 7894895

Group type: EXPERIMENTAL
Intervention: Nephrotic syndrome patients
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (30 donors)
Number of subjects: 68
Study: 2896810

Group type: EXPERIMENTAL
Intervention: Continuing chemotherapy (Arm A)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No further chemotherapy until morphological relapse (Arm B)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No further chemotherapy until increase in myeloblast antigens (Arm C)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Quality of life assessment for arms B and C
Number of subjects: 125
Study: 29358464

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 0
Study: 26660724

Group type: EXPERIMENTAL
Intervention: High-risk condition
Number of subjects: 1046

Group type: COMPARATOR
Intervention: Cultural cognition worldview and negative emotions (sadness and anger)
Number of subjects: 1046
Study: 25321621

Group type: EXPERIMENTAL
Intervention: Remifemin (20 mg bid po)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Tibolone (2.5 mg qd po)
Number of subjects: 116
Study: 22770838

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Placebo acupuncture
Number of subjects: 275

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 275
Study: 20028850

Group type: EXPERIMENTAL
Intervention: Hyperoxia (70% O2)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normoxia (N)
Number of subjects: 7
Study: 18271235

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (48 hours to 1 week after operation) with various acupoints (Neiguan, Qu‐chi, Waiguan, Hegu, Binao, Jianyu, Fengshi, Xuehai, Yinlingquan, Sanyinjiao, Taichong)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Routine treatment of neurosurgical operation and drug treatment (Mannitol, Citioline Sodium, Cefeazidime, etc.)
Number of subjects: 96
Study: 15608034

Group type: EXPERIMENTAL
Intervention: Intracervical sodium nitroprusside gel (10 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 200
Study: 12798839

Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin substitute
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation devices and implantable defibrillators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual chamber pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-wave alternans
Number of subjects: 0
Study: 10426873

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stenting in association with angioplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 0
Study: 8935242

Group type: EXPERIMENTAL
Intervention: Poor families
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpoor families
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression model including poverty, race, site, and representative environmental, maternal, and child variables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poverty and maternal IQ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal distress
Number of subjects: 0
Study: 2010243

Group type: EXPERIMENTAL
Intervention: Dopexamine (0.5 to 6 micrograms/kg/min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Dobutamine (5 to 25 micrograms/kg/min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dopexamine and Dobutamine
Number of subjects: 9
Study: 7037036

Group type: EXPERIMENTAL
Intervention: Salbutamol nebulized with IPPB (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rotacaps (2 x 400 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol nebulized without IPPB
Number of subjects: 0
Study: 31452006

Group type: EXPERIMENTAL
Intervention: Extremely Randomized Trees algorithm for identifying follow-up examinations
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Inter-annotator agreement among three radiologists
Number of subjects: 559
Study: 28985630

Group type: EXPERIMENTAL
Intervention: PEG plus simethicone
Number of subjects: 583

Group type: COMPARATOR
Intervention: PEG alone
Number of subjects: 583
Study: 27121262

Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg (normal hepatic function)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ixazomib 2.3 mg (moderate hepatic impairment)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ixazomib 1.5 mg (severe hepatic impairment)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Overall (moderate/severe hepatic impairment combined)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Recommended starting dose for ixazomib
Number of subjects: 48
Study: 24277763

Group type: EXPERIMENTAL
Intervention: Self-reported dietary data (food frequency questionnaires, 4-day food records, or three 24-hour dietary recalls)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calibration equations using food records or recalls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calibration equations for food frequency questionnaire data
Number of subjects: 0
Study: 22780921

Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate
Number of subjects: 116

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 116
Study: 21069115

Group type: EXPERIMENTAL
Intervention: Incentivised opportunistic chlamydia screening programme with practice education, self-sample collection, and practice incentives for three months.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nurse-led screening strategy
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Doctor-led screening strategy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control practice (no intervention)
Number of subjects: 2
Study: 17425550

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) via vacuum-assisted closure (VAC) device
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard wound therapy (SWT)
Number of subjects: 162
Study: 16330293

Group type: EXPERIMENTAL
Intervention: 4‐mg nicotine lozenge
Number of subjects: 901

Group type: COMPARATOR
Intervention: 4‐mg nicotine gum
Number of subjects: 901
Study: 11989996

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 20
Study: 9459471

Group type: EXPERIMENTAL
Intervention: Cocaine 0.4 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cocaine 0.2 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7888260

Group type: EXPERIMENTAL
Intervention: Intravenous naloxone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Beta endorphin concentrations
Number of subjects: 18
Study: 2145791

Group type: EXPERIMENTAL
Intervention: Procaterol (10 micrograms/inhalation)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Albuterol (90 micrograms/inhalation)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 645799

Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 127

Group type: COMPARATOR
Intervention: Elective cesarean section
Number of subjects: 127
Study: 30922873

Group type: EXPERIMENTAL
Intervention: Obeticholic acid 5 to 10 mg or 10 mg once daily for 12 months, followed by variable adjusted doses during the open-label extension.
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo (during the double-blind phase).
Number of subjects: 193
Study: 28103640

Group type: EXPERIMENTAL
Intervention: DAC (daunorubicin plus cytarabine plus cladribine)
Number of subjects: 171

Group type: COMPARATOR
Intervention: DA (daunorubicin plus cytarabine)
Number of subjects: 171
Study: 25260557

Group type: EXPERIMENTAL
Intervention: MIND at Home intervention
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 289
Study: 24098499

Group type: EXPERIMENTAL
Intervention: PDF copy of the standard paper participant information sheet (PDF‐PIS)
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Electronic Interactive Information Sheet (IIS)
Number of subjects: 1160
Study: 22256223

Group type: EXPERIMENTAL
Intervention: 0.25 Hz 60 pulses rTMS over right SPL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 Hz 60 pulses rTMS over right SPL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 Hz 60 pulses rTMS over right SPL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 Hz 240 pulses rTMS over right SPL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.25 Hz 120 pulses rTMS over right SPL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 Hz 120 pulses rTMS over right SPL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 Hz 120 pulses rTMS over right SPL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rTMS over motor area
Number of subjects: 0
Study: 19402182

Group type: EXPERIMENTAL
Intervention: Captopril LPH 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril LPH 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capoten 50 mg
Number of subjects: 0
Study: 18063208

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg IV
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Metoclopramide and Placebo (both groups)
Number of subjects: 137
Study: 15213582

Group type: EXPERIMENTAL
Intervention: Methylphenidate plus psychosocial treatment (academic remediation, organizational skills training, psychotherapy, parent training, counseling, social skills training)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Methylphenidate plus attention control treatment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Methylphenidate alone
Number of subjects: 103
Study: 11572495

Group type: EXPERIMENTAL
Intervention: Maxillary infiltration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mandibular block
Number of subjects: 60
Study: 9691878

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine, 8 ml/h for 24 hours
Number of subjects: 52

Group type: COMPARATOR
Intervention: 0.2% bupivacaine, 8 ml/h for 24 hours
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison of ropivacaine vs bupivacaine
Number of subjects: 52
Study: 8964876

Group type: EXPERIMENTAL
Intervention: 10 mg E2 valerate
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cyclic increase in serum E2 concentrations in women
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 2100284

Group type: COMPARATOR
Intervention: Naloxone (0.2 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (3 units)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Vasopressin and naloxone combined
Number of subjects: 9
Study: 7307425

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg propranolol intravenously (group 1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (group II)
Number of subjects: 14
Study: 31624837

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg once daily for 16 weeks
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo once daily for 16 weeks
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg once daily
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 31411762

Group type: EXPERIMENTAL
Intervention: DEX infusion 0.5 μg/kg after delivery and PCIA with DEX plus sufentanil
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (infusion with 0.9% normal saline after delivery and PCIA with sufentanil)
Number of subjects: 600
Study: 28146613

Group type: EXPERIMENTAL
Intervention: Aripiprazole Once-Monthly 400 mg (AOM 400)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266